Time to eye opening · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Time to orientation · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Time to discharge from the PACU (in minutes) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Occurrence of intraoperative awareness Time points of measure after surgery: 2 to 6 hours;12 hours; 1 day; 2 days; 3 days; 14 days; 30 days; or time point was not reported Measurement tools: simple questioning; interviews; or structured questionna... · adults undergoing surgery with general anaesthesia
BIS showed no clear difference in occurrence of intraoperative awareness Time points of measure after… compared with ETAG (low certainty).
1 finding from 1 review
Time to eye opening · adults undergoing surgery with general anaesthesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to orientation · adults undergoing surgery with general anaesthesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to discharge from the PACU (in minutes) · adults undergoing surgery with general anaesthesia
1 finding from 1 review
Unimanual capacity · children with unilateral cerebral palsy
2 findings from 1 review
Manual ability ‐ not measured · children with unilateral cerebral palsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐care · children with unilateral cerebral palsy
1 finding from 1 review
Individualised measures of performance · children with unilateral cerebral palsy
1 finding from 1 review
Adverse events · children with unilateral cerebral palsy
1 finding from 1 review
Bimanual performance · children with unilateral cerebral palsy
1 finding from 1 review
Death (all causes) · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in death (all causes) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Graft loss including death · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in total graft loss (with death) compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Biopsy‐proven acute rejection · primary immunosuppression in kidney transplant recipients
Low probably leads to higher biopsy‐proven acute rejection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
CMV infection · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in CMV infection compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Malignancy · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in all malignancy compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (moderate certainty).
1 finding from 1 review
Number needing to change treatment · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in number needing to change treatment compared with higher dose target of rapamycin inhibitor (TOR‐I): primary outcomes (low certainty).
1 finding from 1 review
Diabetes · primary immunosuppression in kidney transplant recipients
Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review